RA 2021 ACR Guidelines - Misc Flashcards

1
Q

What to do with subcutaneous nodules>

A

MTX over alternative DMARDS

progressive SC nodules, switch to non-MTX DMARD over continuation of MTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pulmonary disease (mild + stable airway or parenchymal lung disease)

A

MTX over alternative DMARDs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Heart Failure (NYHA Class III or IV + low response to csDMARDs)

A

non-TNFi or tsDMARD over TNFi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

on TNFi + develop heart failure

A

switch to non-TNFi or tsDMARD over continuation of TNFi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lymphoproliferative disorder

A

rituximab (RTX) over other DMARDs (if RTX is approved)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NAFLD

A

in normal liver enzymes and LFTs with no advanced fibrosis –> MTX over alternative DMARDs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HEP B

A

prophylactic antiviral Rx over monitoring for pts:

  • on RTX who are Heb B core antibody+
  • on bDMARD or tsDMARD who are Hep B core antibody+ and Hep B surface Ag+

frequent monitoring over prophylactic antiviral rx for bDMARD other than RTX or tsDMARD with Hep B core antibody + and HBSAg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hypogammaglobulinemia w/o infection

A

continue RTX over switching to different DMARD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Previous serious infection (w/in past 12 months)

A

add csDMARD over bDMARD or tsDMARD

add/switch DMARD over initiation/increase of GC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Non-tuberculosis mycobacterial lung disease

A

lowest dose of GC or d/c over continuation of GC

csDMARD over bDMARD or tsDMARD

abatacept over other bDMARD and tsDMARD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

methotrexate administration

A

oral MTX recommended over SC (initiation)

initiation/titration to dose >/= 15mg/wk within 4 - 6 weeks (over a dose < 15 mg/wk)

if not tolerating oral MTX, split oral dose (over 24 hours) or SC, and/or increase dose of folic acid, is recommended over switching to alternate DMARDs

if not at target on oral MTX, switch to SC MTX over addition of/switching to alternative DMARDs

MAXIMIZE USE OF MTX PRIOR TO SWITCHING OR ADDING OTHER DMARDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

on triple therapy, if pt on both SSZ and HCQ and need to discontinue one, which is discontinued first?

A

SSZ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

on MTX + bDMARD or tsDMARD who wish to d/c a DMARD…

A

…gradual discontinuation of MTX over gradual discontinuation of the bDMARD of tsDMARD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Low disease activity: HCQ recommended over…

A

…other csDMARD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Low disease activity: SSZ recommended over…

A

…MTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Low disease activity: MTX recommended over…

A

…LEF

17
Q

MTX strongly recommended over…

A

HCQ or SSZ

bDMARD or tsDMARD monoRX

MTX + non-TNFi bDMARD or tsDMARD

18
Q

MTX conditionally recommended over

A

LEF

dual or triple csDMARD

combination of MTX + TNFi

19
Q

initiation of csDMARD w/out short term or long term glucocorticoid is

A

recommended

20
Q

csDMARD-treated, MTX-naive

A

MTX monotherapy OVER MTX + bDMARD or tsDMARD